Business Wire

CMT’s New Report Confirms Increasing Appetite for Connected Insurance in Europe

25.2.2021 18:25:00 EET | Business Wire | Press release

Share

A large shift in driving habits due to the COVID-19 pandemic has changed how people think about motor insurance across Europe, according to a new study by Cambridge Mobile Telematics (CMT), the world’s leading mobile telematics and analytics provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005773/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Based on the surveys of 4,000 drivers in France, Germany, Italy and the U.K., the new report shows shifting attitudes towards quoting channels, claims services, pricing models and value-added services, broken down and analysed by location, age and driving behaviour.

The two surveys - taken in January 2020, before the pandemic, and then nine months later in September 2020 - reveal up to 81 percent of the drivers in Europe have changed how they drive because of COVID-19. Now 65 percent are interested in connected insurance, a 32% jump in nine months.

The pandemic has modified commuting patterns and the average drivers now on the road are much younger, a traditionally riskier driving population. With fewer viable public transport commuting options, younger generations are getting behind the wheel to get to work.

Each country lockdown impacted drivers differently. In the U.K., 66 percent of the respondents said their driving patterns changed and that they are now driving less. 29 percent also noted that they drive for different reasons, and on different days. In France, however, the majority (57 percent) have not really changed driving habits, 12 percent even suggested they drove more.

In this context the survey asked respondents about their preferences in terms of quotes, purchase, claims and motor insurance price models. When asked whether they would be likely to switch to behaviour, distance or reward-based insurance , the September survey showed a major shift in drivers’ expectations.

Respondents were overwhelmingly in favour of switching to usage-based insurance (UBI) at the next renewal if the offer was present. Italian drivers were the most likely at 74 percent of the respondents. 63 percent of British and French drivers were ready to switch, and German appetite for connected insurance grew from 47 percent to 58 percent of drivers willing to switch in the nine months between both surveys.

In the full 50-page report you will find:

  • An analysis of the changes in behaviour relating to driving, pricing, buying, and claiming in four European countries by age, gender, type of roads, and premium paid
  • An overview of four markets’ readiness and appetite for connected insurance and digital claims
  • A breakdown of the top value propositions used today, and how preferences have changed since the onset of COVID-19

“The pandemic uncovered challenges few could have predicted. As a result, typical risk models are no longer enough,” commented Ryan McMahon, VP of Insurance & Government Affairs at CMT. “As driving behaviour changes, the ability to predict risk needs to evolve, insurers will find this report can help identify which European drivers to target with new products.”

The Best Connected Insurance Value Propositions for Europe report is available to downloaded from today.

About Cambridge Mobile Telematics

At Cambridge Mobile Telematics, we show up every day to achieve one goal: to make the world's roads and drivers safer. Founded in 2010 based on MIT research, we are now the world's largest mobile telematics provider, powering 65 enterprise programs in more than 28 countries. Our technology serves several million drivers a day through our partnerships with leading insurers, rideshares, cellular carriers and car makers. We deliver cutting-edge technology to solve the most important problems facing mobility today and to improve road safety across the world.

To learn more, visit www.cmtelematics.com and follow CMT on Twitter @cmtelematics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Hallauer
Cambridge Mobile Telematics
thallauer@cmtelematics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release

Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito

National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release

Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct

Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release

Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release

Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye